NEUROBLASTOMA
Clinical trials for NEUROBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new NEUROBLASTOMA trials appear
Sign up with your email to follow new studies for NEUROBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for kids with tough cancers
Disease control TerminatedThis study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was s…
Matched conditions: NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Tailored cancer cocktail tested for tough childhood tumor
Disease control TerminatedThis trial tested a personalized approach for children with relapsed or hard-to-treat neuroblastoma. Doctors used a tumor biopsy to find genetic changes and then assigned a combination of targeted drugs (ceritinib and ribociclib) to match those changes. The study was terminated e…
Matched conditions: NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Yael P Mosse • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail shows promise for tough childhood cancers
Disease control TerminatedThis early-phase trial tested a combination of three drugs—ribociclib, topotecan, and temozolomide—in children with relapsed or refractory neuroblastoma and other solid tumors. The goal was to find a safe dose and see if the combination could shrink tumors. Only 12 children took …
Matched conditions: NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New radioactive therapy targets tough childhood cancer
Disease control TerminatedThis study tested a radioactive drug called 67Cu-SARTATE in 21 children with high-risk neuroblastoma that had relapsed or not responded to treatment. The drug is designed to deliver radiation directly to tumor cells. The goal was to find the safest dose and see if it shrinks tumo…
Matched conditions: NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 26, 2026 17:47 UTC